language_icon
EN
HI

Biocon Share price

BIOCON

HealthcareLarge Cap

425.65

3.00 (-0.70%)
NSE
BSE
Last updated on 1 Jun, 2026 | 15:48 IST
alert_iconwatchlist_icon
BUYSELL
Today's High

435.00

Today's Low

424.50

52 Week Low

327.60

52 Week High

440.40

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Biocon Chart

Biocon Share Key Metrics

Volume
46.81 L
Market Cap
68993.94 CR
LTQ@LTP
288@425.65
ATP
427.85
Var Margin
15.35 %
Circuit Range
385.8-471.5
Delivery %
59.94 %
Value
200.28 CR
ASM/GSM
No
Market Lot
1

Summary

1 Jun, 2026 | 15:48 को, Biocon का शेयर प्राइस आज ₹425.65 पर है, जो दिन के लिए 3.00% की -0.70 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹424.50 और ₹435.00 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹327.60 से ₹440.40 तक रही है। ट्रेडिंग गतिविधि के मामले में, Biocon ने 4681079 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹1620907773 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹42785 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 288,42565 रही। यह स्टॉक ₹385.8-471.5 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹200.28 CR है। दिन के लिए डिलीवरी परसेंटेज 59.94% रही। इसके अतिरिक्त, Biocon वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Biocon Fundamentals

View More
P/E Ratio

180.02

P/B Ratio

2.04

Div. Yield

0.12

Sector P/E

69.53

Sector P/B

2.99

Sec. Div. Yield

0.55

Biocon Resistance and Support

Pivot 431.43

Resistance

First Resistance

437.21

Second Resistance

445.78

Third Resistance

451.56

Support

First Support

422.86

Second Support

417.08

Third Support

408.51

View More

Biocon Futures & Options

425.65

-3 (-0.7%)

link_white_icon

Biocon Option Chain

View Price, OI, Greeks & More...
View All

30JUN26

428.20

-5.30 (1.22%)

28JUL26

430.70

-4.65 (1.07%)

25AUG26

434.60

-3.55 (0.81%)

BIOCON|30JUN26 CE 425.00

15.00

-4.15 (-21.67%)

BIOCON|30JUN26 PE 430.00

13.5

1.2 (9.76%)

Biocon Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

44.91%

Mutual Fund

16.53%

Insurance

6.16%

Foreign Institutional Investors

7.52%

Domestic Institutional Investors

1.38%

Retail

23.49%

Others

0.01%

Total Promoters
MAR '26
44.91%

Biocon Corporate Actions

DateAgenda
2026-05-07Audited Results & Final Dividend
2026-02-12Quarterly Results

Biocon News

Biocon Ltd - 532523 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Biocon issued a corrigendum to its postal ballot, updating terms for a preferential issue. The issue price is now ₹376.41 per share, and the swap ratio is 0.76159 equity shares for every 100 Biocon Biologics shares, aiming for full ownership of BBL.
May 29 2026 21:16:21

Biocon Limited

Biocon released the transcript of its Q4 FY26 earnings call, detailing a strong year-end performance, successful integration of biosimilar and generic businesses, and significant debt reduction. Management provided a positive outlook on new product launches and increased operating leverage, particularly in H2 FY27.
May 14 2026 16:29:51

Biocon shares gain after Health Canada approval for injection used in treating bloodstream infections

Biocon Pharma Limited, a subsidiary of Biocon, has received approval from Health Canada for its Micafungin for Injection, USP (50 mg and 100 mg). This antifungal medication is indicated for treating various fungal infections in adults and pediatric patients, and for prophylaxis in hematopoietic stem cell transplant patients. This regulatory clearance is expected to enhance Biocon's integrated biosimilars and generics portfolio and expand its presence in the Canadian market.
May 11 2026 10:28:04

Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billion

Biocon's Executive Chairperson, Kiran Mazumdar-Shaw, has named her niece Claire Mazumdar as her successor, outlining a five-year transition plan. The company also announced plans to target peak revenue of $500 million to $700 million from Semaglutide by FY30, with a push starting from FY28, and aims to reduce its current debt of $1.8 billion to $1.1 billion by FY28.
May 11 2026 09:00:00

Biocon Ltd - 532523 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Biocon has initiated a Postal Ballot for shareholder approval on several key resolutions. These include revisions to Executive Chairperson's remuneration, the appointment of Shreehas Pradeep Tambe as CEO & MD, and a preferential issue of equity shares to acquire the remaining minority stake in Biocon Biologics, making it a wholly-owned subsidiary for strategic integration.
May 09 2026 01:28:54

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Biocon announced the availability of the audio and video recording of its Q4 FY26 Earnings Call, held on May 08, 2026. Investors can access the recording via links provided on the company's website.
May 08 2026 21:31:21

Biocon Q4 Results: Net profit down 57% at Rs 198.6 crore

Biocon Ltd. reported a significant decline in its Q4 FY26 net profit, falling 56.8% to ₹198.6 crore, primarily due to an ₹80.4 crore exceptional item. Despite the profit drop, the company's consolidated revenue for the quarter increased to ₹4516.6 crore. For the full fiscal year 2026, net profit also decreased to ₹368.8 crore, while revenue grew to ₹16927 crore.
May 08 2026 10:05:10

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Biocon's monitoring agency report confirms full utilization of over Rs.8,650 crore QIP funds as per stated objects for Q4 FY26. The funds were primarily used for acquisitions and debt repayment across two QIPs.
May 08 2026 00:04:07

Biocon Ltd - 532523 - Outcome Of Board Meeting_Change In Long Term Incentive Plan

Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.
May 07 2026 23:46:24

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Issue of Securities

Biocon's Board approved a preferential issue of 87.92 lakh equity shares at Rs. 376.16 per share, totaling Rs. 330.73 crore. This issuance is to acquire the remaining ~2% stake in its material subsidiary, Biocon Biologics Limited (BBL), aiming for full integration and simplified corporate structure.
May 07 2026 23:44:26
Read More

Biocon Management

NamePosition
Kiran Mazumdar-ShawChairperson
Ravi Rasendra MazumdarNon Independent & Non Executive Director
View More

Biocon FAQs

Biocon शेयर का खरीद मूल्य 425.65 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Biocon शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Biocon शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 180.02 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Biocon शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.04 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Biocon शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.99 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Biocon का मार्केट कैप 68993.94 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Biocon शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 440.40 और 327.60 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Invest with Zero-Cost Demat Account

✓Zero AMC for First Year
✓Free Research Calls
✓₹ 0 Trade & Call Fee
Zero-Cost